ID   EPHB3_HUMAN             Reviewed;         998 AA.
AC   P54753; Q7Z740;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   27-SEP-2005, sequence version 2.
DT   10-MAY-2017, entry version 173.
DE   RecName: Full=Ephrin type-B receptor 3;
DE            EC=2.7.10.1;
DE   AltName: Full=EPH-like tyrosine kinase 2;
DE            Short=EPH-like kinase 2;
DE   AltName: Full=Embryonic kinase 2;
DE            Short=EK2;
DE            Short=hEK2;
DE   AltName: Full=Tyrosine-protein kinase TYRO6;
DE   Flags: Precursor;
GN   Name=EPHB3; Synonyms=ETK2, HEK2, TYRO6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], IDENTIFICATION OF EFNB1 AND EFNB2 AS
RP   LIGANDS, AND AUTOPHOSPHORYLATION.
RC   TISSUE=Embryo;
RX   PubMed=8397371;
RA   Boehme B., Holtrich U., Wolf G., Luzius H., Grzeschik K.-H.,
RA   Strebhardt K., Ruebsamen-Waigmann H.;
RT   "PCR mediated detection of a new human receptor-tyrosine-kinase, HEK
RT   2.";
RL   Oncogene 8:2857-2862(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NOMENCLATURE.
RX   PubMed=9267020;
RG   Eph nomenclature committee;
RT   "Unified nomenclature for Eph family receptors and their ligands, the
RT   ephrins.";
RL   Cell 90:403-404(1997).
RN   [4]
RP   PHOSPHORYLATION AT TYR-614, AND MUTAGENESIS OF TYR-614 AND LYS-665.
RX   PubMed=9674711; DOI=10.1038/sj.onc.1201907;
RA   Hock B., Boehme B., Karn T., Feller S., Ruebsamen-Waigmann H.,
RA   Strebhardt K.;
RT   "Tyrosine-614, the major autophosphorylation site of the receptor
RT   tyrosine kinase HEK2, functions as multi-docking site for SH2-domain
RT   mediated interactions.";
RL   Oncogene 17:255-260(1998).
RN   [5]
RP   AUTOPHOSPHORYLATION, FUNCTION IN CELL ADHESION, FUNCTION IN CELL
RP   MIGRATION, AND SUBCELLULAR LOCATION.
RX   PubMed=15536074; DOI=10.1074/jbc.M411383200;
RA   Miao H., Strebhardt K., Pasquale E.B., Shen T.L., Guan J.L., Wang B.;
RT   "Inhibition of integrin-mediated cell adhesion but not directional
RT   cell migration requires catalytic activity of EphB3 receptor tyrosine
RT   kinase. Role of Rho family small GTPases.";
RL   J. Biol. Chem. 280:923-932(2005).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 39-211, AND DISULFIDE BOND.
RG   Structural genomics consortium (SGC);
RT   "Ligand binding domain of human EPHB3.";
RL   Submitted (JAN-2011) to the PDB data bank.
RN   [8]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-168; CYS-440; VAL-579; LEU-601 AND
RP   TRP-724.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously
CC       transmembrane ephrin-B family ligands residing on adjacent cells,
CC       leading to contact-dependent bidirectional signaling into
CC       neighboring cells. The signaling pathway downstream of the
CC       receptor is referred to as forward signaling while the signaling
CC       pathway downstream of the ephrin ligand is referred to as reverse
CC       signaling. Generally has an overlapping and redundant function
CC       with EPHB2. Like EPHB2, functions in axon guidance during
CC       development regulating for instance the neurons forming the corpus
CC       callosum and the anterior commissure, 2 major interhemispheric
CC       connections between the temporal lobes of the cerebral cortex. In
CC       addition to its role in axon guidance plays also an important
CC       redundant role with other ephrin-B receptors in development and
CC       maturation of dendritic spines and the formation of excitatory
CC       synapses. Controls other aspects of development through regulation
CC       of cell migration and positioning. This includes angiogenesis,
CC       palate development and thymic epithelium development for instance.
CC       Forward and reverse signaling through the EFNB2/EPHB3 complex also
CC       regulate migration and adhesion of cells that tubularize the
CC       urethra and septate the cloaca. Finally, plays an important role
CC       in intestinal epithelium differentiation segregating progenitor
CC       from differentiated cells in the crypt.
CC       {ECO:0000269|PubMed:15536074}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- SUBUNIT: Heterotetramer upon binding of the ligand. The
CC       heterotetramer is composed of an ephrin dimer and a receptor
CC       dimer. Oligomerization is probably required to induce biological
CC       responses (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15536074};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:15536074}.
CC       Cell projection, dendrite {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Ubiquitous.
CC   -!- PTM: Phosphorylated. Autophosphorylates upon ligand-binding.
CC       Autophosphorylation on Tyr-614 is required for interaction with
CC       SH2 domain-containing proteins. {ECO:0000269|PubMed:9674711}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X75208; CAA53021.1; -; mRNA.
DR   EMBL; BC052968; AAH52968.1; -; mRNA.
DR   CCDS; CCDS3268.1; -.
DR   PIR; S37627; S37627.
DR   RefSeq; NP_004434.2; NM_004443.3.
DR   UniGene; Hs.2913; -.
DR   PDB; 3P1I; X-ray; 2.10 A; A/B/C=39-211.
DR   PDB; 3ZFY; X-ray; 2.20 A; A/B=616-910.
DR   PDB; 5L6O; X-ray; 1.88 A; A=616-910.
DR   PDB; 5L6P; X-ray; 2.26 A; A=616-910.
DR   PDBsum; 3P1I; -.
DR   PDBsum; 3ZFY; -.
DR   PDBsum; 5L6O; -.
DR   PDBsum; 5L6P; -.
DR   ProteinModelPortal; P54753; -.
DR   SMR; P54753; -.
DR   BioGrid; 108363; 12.
DR   IntAct; P54753; 5.
DR   MINT; MINT-1538099; -.
DR   STRING; 9606.ENSP00000332118; -.
DR   BindingDB; P54753; -.
DR   ChEMBL; CHEMBL4901; -.
DR   GuidetoPHARMACOLOGY; 1832; -.
DR   iPTMnet; P54753; -.
DR   PhosphoSitePlus; P54753; -.
DR   BioMuta; EPHB3; -.
DR   DMDM; 76803655; -.
DR   EPD; P54753; -.
DR   MaxQB; P54753; -.
DR   PaxDb; P54753; -.
DR   PeptideAtlas; P54753; -.
DR   PRIDE; P54753; -.
DR   DNASU; 2049; -.
DR   Ensembl; ENST00000330394; ENSP00000332118; ENSG00000182580.
DR   GeneID; 2049; -.
DR   KEGG; hsa:2049; -.
DR   UCSC; uc003foz.4; human.
DR   CTD; 2049; -.
DR   DisGeNET; 2049; -.
DR   GeneCards; EPHB3; -.
DR   HGNC; HGNC:3394; EPHB3.
DR   HPA; CAB034350; -.
DR   HPA; HPA007698; -.
DR   HPA; HPA008184; -.
DR   MIM; 601839; gene.
DR   neXtProt; NX_P54753; -.
DR   OpenTargets; ENSG00000182580; -.
DR   PharmGKB; PA27826; -.
DR   eggNOG; KOG0196; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118975; -.
DR   HOGENOM; HOG000233856; -.
DR   HOVERGEN; HBG062180; -.
DR   InParanoid; P54753; -.
DR   KO; K05112; -.
DR   OMA; ELAWTAH; -.
DR   OrthoDB; EOG091G00W0; -.
DR   PhylomeDB; P54753; -.
DR   TreeFam; TF315608; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928664; Ephrin signaling.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   SignaLink; P54753; -.
DR   SIGNOR; P54753; -.
DR   EvolutionaryTrace; P54753; -.
DR   GeneWiki; EPHB3; -.
DR   GenomeRNAi; 2049; -.
DR   PRO; PR:P54753; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000182580; -.
DR   CleanEx; HS_EPHB3; -.
DR   Genevisible; P54753; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008046; F:axon guidance receptor activity; IEA:Ensembl.
DR   GO; GO:0005003; F:ephrin receptor activity; IDA:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; ISS:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; ISS:UniProtKB.
DR   GO; GO:0007413; P:axonal fasciculation; ISS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IDA:UniProtKB.
DR   GO; GO:0021952; P:central nervous system projection neuron axonogenesis; IEA:Ensembl.
DR   GO; GO:0022038; P:corpus callosum development; ISS:UniProtKB.
DR   GO; GO:0060996; P:dendritic spine development; ISS:UniProtKB.
DR   GO; GO:0060997; P:dendritic spine morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048546; P:digestive tract morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0060021; P:palate development; ISS:UniProtKB.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0050770; P:regulation of axonogenesis; ISS:UniProtKB.
DR   GO; GO:0022407; P:regulation of cell-cell adhesion; IDA:UniProtKB.
DR   GO; GO:0043087; P:regulation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:0031290; P:retinal ganglion cell axon guidance; IEA:Ensembl.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IDA:UniProtKB.
DR   GO; GO:0048538; P:thymus development; ISS:UniProtKB.
DR   GO; GO:0001655; P:urogenital system development; ISS:UniProtKB.
DR   CDD; cd10478; EphR_LBD_B3; 1.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.120.260; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR027936; Eph_TM.
DR   InterPro; IPR034245; EphB3_rcpt_lig-bd.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016257; Tyr_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_kinase_rcpt_V_CS.
DR   Pfam; PF14575; EphA2_TM; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF07699; Ephrin_rec_like; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00536; SAM_1; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM01411; Ephrin_rec_like; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51550; EPH_LBD; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Angiogenesis; ATP-binding; Cell membrane;
KW   Cell projection; Complete proteome; Developmental protein;
KW   Disulfide bond; Glycoprotein; Kinase; Membrane; Neurogenesis;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL        1     33       {ECO:0000255}.
FT   CHAIN        34    998       Ephrin type-B receptor 3.
FT                                /FTId=PRO_0000016831.
FT   TOPO_DOM     34    559       Extracellular. {ECO:0000255}.
FT   TRANSMEM    560    580       Helical. {ECO:0000255}.
FT   TOPO_DOM    581    998       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       39    217       Eph LBD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00883}.
FT   DOMAIN      339    451       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      452    545       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      633    896       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      925    989       SAM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00184}.
FT   NP_BIND     639    647       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF       996    998       PDZ-binding. {ECO:0000255}.
FT   COMPBIAS    199    336       Cys-rich.
FT   ACT_SITE    758    758       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     665    665       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     614    614       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:9674711}.
FT   CARBOHYD    351    351       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    445    445       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     81    199       {ECO:0000269|Ref.7}.
FT   VARIANT     168    168       R -> L (in a lung small cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042176.
FT   VARIANT     440    440       R -> C (in dbSNP:rs56029711).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042177.
FT   VARIANT     579    579       I -> V (in dbSNP:rs56103851).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042178.
FT   VARIANT     601    601       I -> L (in dbSNP:rs56129875).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042179.
FT   VARIANT     724    724       R -> W (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation;
FT                                dbSNP:rs371378866).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042180.
FT   MUTAGEN     614    614       Y->F: Partial loss of phosphorylation and
FT                                loss of interaction with SH2-containing
FT                                proteins. {ECO:0000269|PubMed:9674711}.
FT   MUTAGEN     665    665       K->R: Kinase-dead. Loss of
FT                                autophosphorylation.
FT                                {ECO:0000269|PubMed:9674711}.
FT   CONFLICT    367    367       G -> V (in Ref. 1; CAA53021).
FT                                {ECO:0000305}.
FT   CONFLICT    406    408       TER -> SEP (in Ref. 1; CAA53021).
FT                                {ECO:0000305}.
FT   CONFLICT    412    412       I -> T (in Ref. 1; CAA53021).
FT                                {ECO:0000305}.
FT   STRAND       39     44       {ECO:0000244|PDB:3P1I}.
FT   HELIX        45     47       {ECO:0000244|PDB:3P1I}.
FT   STRAND       55     58       {ECO:0000244|PDB:3P1I}.
FT   STRAND       63     68       {ECO:0000244|PDB:3P1I}.
FT   STRAND       74     80       {ECO:0000244|PDB:3P1I}.
FT   STRAND       85     87       {ECO:0000244|PDB:3P1I}.
FT   STRAND       90     93       {ECO:0000244|PDB:3P1I}.
FT   STRAND      103    114       {ECO:0000244|PDB:3P1I}.
FT   HELIX       116    118       {ECO:0000244|PDB:3P1I}.
FT   STRAND      130    139       {ECO:0000244|PDB:3P1I}.
FT   STRAND      155    160       {ECO:0000244|PDB:3P1I}.
FT   STRAND      175    181       {ECO:0000244|PDB:3P1I}.
FT   STRAND      186    198       {ECO:0000244|PDB:3P1I}.
FT   STRAND      200    210       {ECO:0000244|PDB:3P1I}.
FT   STRAND      633    640       {ECO:0000244|PDB:5L6O}.
FT   STRAND      646    652       {ECO:0000244|PDB:5L6O}.
FT   STRAND      655    657       {ECO:0000244|PDB:5L6P}.
FT   STRAND      660    666       {ECO:0000244|PDB:5L6O}.
FT   HELIX       673    687       {ECO:0000244|PDB:5L6O}.
FT   STRAND      697    701       {ECO:0000244|PDB:5L6O}.
FT   STRAND      703    706       {ECO:0000244|PDB:5L6O}.
FT   STRAND      708    712       {ECO:0000244|PDB:5L6O}.
FT   HELIX       719    725       {ECO:0000244|PDB:5L6O}.
FT   TURN        726    728       {ECO:0000244|PDB:5L6O}.
FT   HELIX       732    751       {ECO:0000244|PDB:5L6O}.
FT   HELIX       761    763       {ECO:0000244|PDB:5L6O}.
FT   STRAND      764    766       {ECO:0000244|PDB:5L6O}.
FT   STRAND      772    774       {ECO:0000244|PDB:5L6O}.
FT   STRAND      791    793       {ECO:0000244|PDB:5L6O}.
FT   STRAND      796    798       {ECO:0000244|PDB:5L6P}.
FT   HELIX       802    804       {ECO:0000244|PDB:5L6O}.
FT   HELIX       807    812       {ECO:0000244|PDB:5L6O}.
FT   HELIX       817    832       {ECO:0000244|PDB:5L6O}.
FT   TURN        838    841       {ECO:0000244|PDB:5L6O}.
FT   HELIX       844    852       {ECO:0000244|PDB:5L6O}.
FT   HELIX       865    874       {ECO:0000244|PDB:5L6O}.
FT   TURN        879    881       {ECO:0000244|PDB:5L6O}.
FT   HELIX       885    897       {ECO:0000244|PDB:5L6O}.
FT   HELIX       899    902       {ECO:0000244|PDB:5L6O}.
SQ   SEQUENCE   998 AA;  110330 MW;  9B65A4EF58B27407 CRC64;
     MARARPPPPP SPPPGLLPLL PPLLLLPLLL LPAGCRALEE TLMDTKWVTS ELAWTSHPES
     GWEEVSGYDE AMNPIRTYQV CNVRESSQNN WLRTGFIWRR DVQRVYVELK FTVRDCNSIP
     NIPGSCKETF NLFYYEADSD VASASSPFWM ENPYVKVDTI APDESFSRLD AGRVNTKVRS
     FGPLSKAGFY LAFQDQGACM SLISVRAFYK KCASTTAGFA LFPETLTGAE PTSLVIAPGT
     CIPNAVEVSV PLKLYCNGDG EWMVPVGACT CATGHEPAAK ESQCRPCPPG SYKAKQGEGP
     CLPCPPNSRT TSPAASICTC HNNFYRADSD SADSACTTVP SPPRGVISNV NETSLILEWS
     EPRDLGGRDD LLYNVICKKC HGAGGASACS RCDDNVEFVP RQLGLTERRV HISHLLAHTR
     YTFEVQAVNG VSGKSPLPPR YAAVNITTNQ AAPSEVPTLR LHSSSGSSLT LSWAPPERPN
     GVILDYEMKY FEKSEGIAST VTSQMNSVQL DGLRPDARYV VQVRARTVAG YGQYSRPAEF
     ETTSERGSGA QQLQEQLPLI VGSATAGLVF VVAVVVIAIV CLRKQRHGSD SEYTEKLQQY
     IAPGMKVYID PFTYEDPNEA VREFAKEIDV SCVKIEEVIG AGEFGEVCRG RLKQPGRREV
     FVAIKTLKVG YTERQRRDFL SEASIMGQFD HPNIIRLEGV VTKSRPVMIL TEFMENCALD
     SFLRLNDGQF TVIQLVGMLR GIAAGMKYLS EMNYVHRDLA ARNILVNSNL VCKVSDFGLS
     RFLEDDPSDP TYTSSLGGKI PIRWTAPEAI AYRKFTSASD VWSYGIVMWE VMSYGERPYW
     DMSNQDVINA VEQDYRLPPP MDCPTALHQL MLDCWVRDRN LRPKFSQIVN TLDKLIRNAA
     SLKVIASAQS GMSQPLLDRT VPDYTTFTTV GDWLDAIKMG RYKESFVSAG FASFDLVAQM
     TAEDLLRIGV TLAGHQKKIL SSIQDMRLQM NQTLPVQV
//
